(Reuters) - The maker of automated blood-processing systems and
disposable products also said it named Chief Operating officer
William Osgood as the chief executive officer.
Osgood replaces Phil Coelho, who will remain with the
company as the chief technology architect.
In a separate statement, the company said it received U.S.
regulatory approval to market its CryoSeal fibrin sealant in
liver resection surgery.
Read more at Reuters.com Government Filings News
disposable products also said it named Chief Operating officer
William Osgood as the chief executive officer.
Osgood replaces Phil Coelho, who will remain with the
company as the chief technology architect.
In a separate statement, the company said it received U.S.
regulatory approval to market its CryoSeal fibrin sealant in
liver resection surgery.
Read more at Reuters.com Government Filings News
No comments:
Post a Comment